tradingkey.logo
tradingkey.logo
Suchen

Impact Biomedical Inc

IBO
Zur Watchlist hinzufügen
0.472USD
+0.003+0.68%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
50.89MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Impact Biomedical Inc Unternehmen

Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.

Impact Biomedical Inc Informationen

BörsenkürzelIBO
Name des UnternehmensImpact Biomedical Inc
IPO-datumSep 16, 2024
CEOHeuszel (Frank D)
Anzahl der mitarbeiter2
WertpapierartOrdinary Share
GeschäftsjahresendeSep 16
Addresse1400 Broadfield Blvd.
StadtHOUSTON
BörseNASDAQ OMX – NASDAQ Basic Amex
LandUnited States of America
Postleitzahl77084
Telefon15852321500
Websitehttps://www.impactbiomedinc.com/
BörsenkürzelIBO
IPO-datumSep 16, 2024
CEOHeuszel (Frank D)

Führungskräfte von Impact Biomedical Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
300.00K
--
Dr. Elise Brownell
Dr. Elise Brownell
Independent Director
Independent Director
300.00K
--
Ms. Melissa Sims
Ms. Melissa Sims
Independent Director
Independent Director
300.00K
--
Mr. Christian Zimmerman
Mr. Christian Zimmerman
Independent Director
Independent Director
300.00K
--
Mr. Castel B. Hibbert
Mr. Castel B. Hibbert
Independent Director
Independent Director
300.00K
--
Mr. Jason Grady
Mr. Jason Grady
Director
Director
250.18K
-19.99%
Mr. Heng Fai (Ambrose) Chan
Mr. Heng Fai (Ambrose) Chan
Director
Director
--
--
Mr. Frank D. Heuszel, CPA
Mr. Frank D. Heuszel, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Todd D. Macko
Mr. Todd D. Macko
Chief Financial Officer
Chief Financial Officer
--
--
Mr. David K. Keene
Mr. David K. Keene
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
300.00K
--
Dr. Elise Brownell
Dr. Elise Brownell
Independent Director
Independent Director
300.00K
--
Ms. Melissa Sims
Ms. Melissa Sims
Independent Director
Independent Director
300.00K
--
Mr. Christian Zimmerman
Mr. Christian Zimmerman
Independent Director
Independent Director
300.00K
--
Mr. Castel B. Hibbert
Mr. Castel B. Hibbert
Independent Director
Independent Director
300.00K
--
Mr. Jason Grady
Mr. Jason Grady
Director
Director
250.18K
-19.99%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Impact Biomedical Inc?

Die fünf größten Anteilseigner von Impact Biomedical Inc sind: Mr. Mark Suseck

Wie viele Institutionen halten Anteile an Impact Biomedical Inc (IBO)?

Mit Stand vom 2026Q1 halten 37 Institutionen Anteile an Impact Biomedical Inc, mit einem Gesamtmarktwert von etwa 2.77M, was 2.56% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 2084658.00 gestiegen.